ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1171

Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease

Phan Saligrama1, Erin Wilfong2, Elise Rizzi3, Leslie Crofford2 and Peggy Kendall1, 1Washington University, Saint Louis, MO, 2Vanderbilt University Medical Center, Nashville, TN, 3Pennsylvania State University, Hershey, PA

Meeting: ACR Convergence 2022

Keywords: immunology, interstitial lung disease, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease remains unclear. We aimed to evaluate whether distinct immune cell subsets in peripheral blood are enriched or reduced in scleroderma patients with interstitial lung disease as compared to scleroderma without interstitial lung disease and healthy controls.

Methods: Peripheral blood was collected from scleroderma patients with or without interstitial lung disease who met the 2013 ACR scleroderma classification criteria, and matched healthy donors. We used a 38-parameter mass cytometry by time-of-flight panel to characterize lymphocyte and myeloid subsets. Dimensionality reduction algorithm t-distributed stochastic neighbor embedding (t-SNE) followed by supervised gating was performed to distinguish immune cell subsets. The p values were calculated using Kruskal-Wallis H test and Mann-Whitney + FDR for multiple test correction, as appropriate, using Cytobank platform.

Results: We identified decreased frequencies in CD4+ T cells in peripheral blood of scleroderma patients with interstitial lung disease (n=24, 28.01 ± 6.534%) as compared to healthy donors (n=18, 38.99 ± 6.76%, p=0.00012). CD8+ T cells were reduced in frequencies in scleroderma patients without interstitial lung disease (n=16, 14.97 ± 7.496%) versus healthy donors (22.45 ± 5.937%, p=0.01774). Proportions of B cells were lower in scleroderma patients with interstitial lung disease (6.404 ± 4.294%) compared to without interstitial lung disease (10.64 ± 5.331%, p=0.04529) and healthy donors (10.47 ± 4.579%, p=0.02010). Scleroderma patients with interstitial lung disease (4.371 ± 2.125%) were determined to have higher proportions of dendritic cells compared to without interstitial lung disease (2.766 ± 1.291%, p= 0.02611) and healthy donors (1.897 ± 0.802%, p=0.00011). We also found increased frequencies of non-classical monocytes in scleroderma patients with interstitial lung disease (4.082 ± 2.194%) versus healthy donors (1.811 ± 0.7086%, p=0.00011) as well as higher proportions of classical monocytes in scleroderma with (18.75 ± 7.098, p=0.00011) or without interstitial lung disease (18.55 ± 7.281%, p=0.00091) compared to healthy donors (9.254 ± 3.368%).

Conclusion: Patients with scleroderma-interstitial lung disease have distinct immune cell profile compared to healthy control donors. B cell and dendritic cell compartments appear to distinctly correlate with the presence or absence of interstitial lung disease in systemic sclerosis. Further work to investigate these populations may elucidate putative disease biomarkers or therapeutic drugs.


Disclosures: P. Saligrama, Boehringer-Ingelheim; E. Wilfong, Boehringer-Ingelheim, Department of Justice/Health and Human Services - Vaccine Injury Compensation Program; E. Rizzi, None; L. Crofford, None; P. Kendall, None.

To cite this abstract in AMA style:

Saligrama P, Wilfong E, Rizzi E, Crofford L, Kendall P. Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/distinct-immune-cell-subsets-in-systemic-sclerosis-related-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-immune-cell-subsets-in-systemic-sclerosis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology